Chronoscale Holdings Corp annual report, FY2013

SEC Filing Summary

Entity and period: The supplied filing identifies the registrant as PN Med Group Inc., not Chronoscale Holdings Corp. It is a Form 10-K for the fiscal year ended March 31, 2013; it does not report a period described as “2012 Q4.” The company is a development-stage medical-supplies distributor planning to serve customers in Chile and had not commenced sales operations.

Financial results and liquidity

MetricFY ended March 31, 2013Prior comparable period
Revenue$0$0
Operating expenses and net loss$12,292$4,657 from inception through March 31, 2012
Cash and total assets, at period end$29,175$8,443
Total liabilities, at period end$14,124$8,100
Stockholders’ equity, at period end$15,051$343
Cash used in operating activities$11,992$157 from inception through March 31, 2012
Cash provided by financing activities$32,724$8,600 from inception through March 31, 2012

FY 2013 operating expenses consisted primarily of professional fees ($10,941), plus website expenses ($500), bank fees ($310), and business-license and permit expenses ($541). No gross margin is reported because there were no sales. Period-end liabilities included $9,324 in unsecured, non-interest-bearing shareholder loans due on demand and $4,800 in accrued expenses. The company reported no bank credit facility. Management said existing funds and anticipated financing were expected to support operations for about six months, but additional capital would be needed for longer-term requirements.

Changes, outlook, and material risks

  • Net loss increased to $12,292 from $4,657 in the initial period ended March 31, 2012. Cash increased by $20,732 during FY 2013, supported by $27,000 of stock-sale proceeds and $5,724 of additional director/shareholder loans.
  • The company had a supplier agreement with Kangtai Medical Devices Co. of China, but had no executed purchase commitments from prospective Chilean customers. Customer interest was preliminary and nonbinding. The stated business plan included importing products, with an expected delivery lead time of two to three months.
  • The independent auditor’s report included an explanatory paragraph raising substantial doubt about the company’s ability to continue as a going concern. Management expected to seek additional equity or debt financing; availability and terms were uncertain, and additional equity or convertible debt could dilute existing shareholders.
  • Management disclosed material weaknesses in internal control over financial reporting: no independent audit committee oversight, inadequate cash controls and segregation of duties, and no formal data-backup or off-site storage procedures. Management concluded controls were not effective as of March 31, 2013; no material improvement was reported during the fourth quarter.
  • The filing identifies the company as a shell company. It reported no established active trading market and no shares traded as of March 31, 2013. The company reported no material commitments, off-balance-sheet arrangements, or pending legal proceedings.

Key facts for investors to verify

  • Confirm the issuer and reporting period: the supplied filing is for PN Med Group Inc. and FY ended March 31, 2013, despite the request metadata naming Chronoscale Holdings Corp. and 2012 Q4.
  • Verify whether the company subsequently began operations, generated revenue, and secured binding customer orders or inventory financing.
  • Review current cash needs, financing availability, and the status and repayment terms of the $9,324 related-party loan due on demand.
  • Check whether the disclosed control weaknesses were remediated and whether the company’s shell-company and trading-market status changed.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.